DarioHealth Corp. (DRIO)
NASDAQ (CM) NASDAQ (CM) Primary 
DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript
DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript
DarioHealth Q1 Earnings Call Highlights
DarioHealth NASDAQ: DRIO reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on the company's first-quarter 2026 earnings call Wednesday.
DarioHealth Corp. (DRIO) Reports Q1 Loss, Beats Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $1.2 per share a year ago.
DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to earnings of $0.2 per share a year ago.
DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript
DarioHealth Corp. ( DRIO ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Zoe Harrison Erez Raphael - CEO & Director Steven Nelson - President & Chief Commercial Officer Chen Franco-Yehuda - CFO, Treasurer & Secretary Conference Call Participants Lucas Romanski - TD Cowen, Research Division Theodore O'Neill - Litchfield Hills Research, LLC Presentation Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2025 Results Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025.
DarioHealth Corp. (DRIO) Reports Q3 Loss, Lags Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.63. This compares to a loss of $2.6 per share a year ago.
Wall Street Analysts Predict a 42.77% Upside in DarioHealth (DRIO): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in DarioHealth (DRIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to earnings of $0.06 per share a year ago.
DarioHealth Corp. (DRIO) Q2 2025 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Chen Franco-Yehuda - CFO, Treasurer & Secretary Erez Raphael - CEO & Director Steven C. Nelson - President & Chief Commercial Officer Zoe Harrison - Corporate Participant Conference Call Participants Theodore Rudd O'Neill - Litchfield Hills Research, LLC Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Second Quarter 2025 Results Conference Call.
DarioHealth Corp. (DRIO) Q1 2025 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Lara Dodo - Acting Chief Operating Officer Conference Call Participants Charles Yi - TD Securities David Grossman - Stifel Nicolaus Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth First Quarter 2025 Results Conference Call. At this time, all lines are in a listen-only mode.
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.20 per share a year ago.
DarioHealth (DRIO) Upgraded to Strong Buy: Here's What You Should Know
DarioHealth (DRIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
